Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Investor Day (October 2022)
7 slides from Celon Pharma Sa's investor day presentation, October 2022
Slide 1: Oncology
Oncology Angelika Judycka Clinical Development Leader Celon Pharma Investor Day 2022
Slide 2: CPL'110 – Projects
CPL’110 — Projects CLINICAL DEVELOPMENT INDICATION MOLECULAR TARGET RESEARCH PRE-CLINICAL DEVELOPMENT PHASE! PHASE II Solid tumours FGFR Inhibitors CPL'110 Solid tumours UBAT Inhibitors / haematological cancers Solid tumours 7
Slide 3: CPL'110 – Study design, Part 1
CPL’110 – Study design Part 1 Part 1 of the study enrolled 15 people with refractory solid malignancies, with no further treatment options, who meet the general eligibility criteria. Study participants Patients (n=15) IMP doses 12,5 mg 25 mg 50 mg 100 mg
Slide 4: CPL'110 – Study design, Part 2 and 3
CPL’110 – Study design Part 2 and 3 Parts 2 and 3 include patients who meet the general inclusion criteria and who tested positive for FGFR molecular alteration. Patients Study participants (n=30) IMP doses 175 mg 350 mg 550 mg 700 mg IMP interim doses 150 mg 125 mg 325 mg 300 mg 525 mg 500 mg 675 m
Slide 5: Daily dosage
Parts of 01FGFR2018 clinical study 1. Initial dose escalation • Dosage in cohorts Maximum of 4 cohorts envisaged by the protocol 750 700 650 2. Dose escalation ∎ 600 Maximum of 4 cohorts envisaged by the 550 protocol 500 Daily dosage 450 (-) FGFR eligibility 3. Dose extension x 400 Maximum of 2 coho
Slide 6: CPL'110 – Study recruitment
CPL’110 — Study recruitment 2 (CN cholanziocarcinoma treatment ongoing Patients with > |QUUEEEEENNNNNNNNND prostate cancer treatment ongoing confirmed FGFR 8 | QUE cholangiocarcinoma (metastasis: lung cancer) treatment ongoing aberration | LLL skin cancer treatment ongoing 75me/ad z = Py E s a patie
Slide 7: Angelika Judycka, Clinical Development Leader
Angelika Judycka Clinical Development Leader angelika.judycka@celonpharma.com Celon Pharma Investor Day 2022